Skye Bioscience, Inc.

No quarterly revenue, EPS, gross margin, or year-over-year operating figures were provided in the transcript. Management said Skye ended 2025 with $25.7 million in cash, cash equivalents and short-term investments, and said it is managing the operating plan to extend runway through Q4 2026. Forward-looking clinical milestones include interim CBeyond extension data in Q1, completion of ENHANZE compatibility and in-use work, Cohort 2 enrollment in Q2, and top-line expansion study data plus planned Phase IIb final study design in Q4 2026.

Punit Dhillon emphasized that Skye has moved from an initial signal to a more coherent development case for nimacimab, especially as an add-on to GLP-1 therapy rather than a competing first-line obesity drug. His tone was confident but measured: he repeatedly framed the next step as proving the exposure-safety-durability relationship at higher doses and building a practical subcutaneous path before Phase IIb. He also highlighted capital discipline, saying the company had aligned costs to the work that matters most and is targeting runway through Q4 2026.

No formal CFO remarks were included, but management comments covered cash and capital allocation. Punit Dhillon said Skye ended 2025 with $25.7 million in cash, cash equivalents and short-term investments, and that the company has been managing its operating plan to extend runway through Q4 2026. He also said the team took steps to align the cost structure with the highest-priority R&D and clinical work, including the new CBeyond expansion and Phase IIb planning.

Analysts focused on how quickly Skye can share higher-dose data, whether the company needs even higher doses, and how the Halozyme-enabled formulation will work. Management said the Part C IV cohorts are the fastest way to generate high-exposure safety and PK data, with doses selected to confirm a clear exposure step-up and preserve CNS sparing; they said efficacy is not the primary readout, though any monotherapy directionality would matter. On formulation, management said ENHANZE work is ongoing and intended for Phase IIb, while IV is being used now to accelerate data generation; they also confirmed a self-administered or commercial-type delivery path would be addressed later, with an auto-injector concept tied to Phase III rather than the current study.